CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 26, 2019-- Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 14, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that

- BT5528 targets EphA2, an antigen believed to be overexpressed in tumor types with high unmet need and a target for which antibody-based approaches have been unsuccessful to date - Phase I dose escalation has commenced in the U.S and will be conducted at sites in both the U.S.

- BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies - Preclinical data on Bicycle® tumor-targeted immune cell agonists to be presented at SITC Annual Meeting on November 9, 2019 - Cash was $96.0 million at September 30, 2019 , which excludes $6.0 million UK R&D

- BT7480 has been selected as the Company’s lead immuno-oncology candidate to advance into IND-enabling studies CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 5, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Oct. 31, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of Veronica

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Oct. 29, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced the appointment of Nigel

Bicycle to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and CNS drug development CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Oct. 22, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Oct. 16, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycles® ) product platform, today announced that new

  - Phase I dose escalation continues; dosing is within the therapeutic range predicted by preclinical models     - Early analysis of data shows stable disease in 54% of evaluable patients at eight weeks, across all cohorts of the all-comers Phase I escalation     - Tumor biopsies indicate targeted